Table 2 Decrease in lipid and apolipoprotein measures from baseline to end of treatment
| Â | Placebo Q4W (N=6) | 75 mg Q4W (N=10) | 150 mg Q4W (N=20) | Placebo Q8W (N=6) | 150 mg Q8W (N=10) | 300 mg Q8W (N=20) | Placebo Q12W (N=7) | 300 mg Q12W (N=10) | 450 mg Q12W (N=21) |
|---|---|---|---|---|---|---|---|---|---|
TC | |||||||||
 Baseline (mmol/L) | 4.570 (0.165) | 5.169 (0.329) | 5.352 (0.167) | 5.223 (0.358) | 5.304 (0.271) | 5.455 (0.174) | 5.830 (0.473) | 5.186 (0.232) | 5.081 (0.191) |
 Percentage change from baseline to end of treatment (%) | 1.578 (5.877) | −32.940 (3.048) | −34.162 (3.234) | −3.065 (4.836) | −37.760 (3.432) | −31.576 (3.516) | 3.534 (5.057) | −31.263 (5.005) | −35.339 (3.186) |
Non-HDL-C | |||||||||
 Baseline (mmol/L) | 3.220 (0.241) | 4.116 (0.304) | 4.071 (0.170) | 4.020 (0.399) | 4.032 (0.225) | 4.281 (0.183) | 4.179 (0.360) | 4.029 (0.223) | 3.780 (0.182) |
 Percentage change from baseline to end of treatment (%) | 2.746 (8.305) | −46.991 (3.605) | −49.979 (4.396) | −5.957 (6.166) | −52.349 (3.301) | −39.920 (4.441) | 7.412 (6.497) | −43.542 (6.503) | −47.383 (3.900) |
ApoB | |||||||||
 Baseline (g/L) | 0.908 (0.065) | 1.151 (0.070) | 1.112 (0.050) | 1.115 (0.095) | 1.094 (0.059) | 1.194 (0.053) | 1.191 (0.085) | 1.106 (0.058) | 1.072 (0.046) |
 Percentage change from baseline to end of treatment (%) | 7.087 (7.955) | −43.392 (3.719) | −47.026 (4.180) | −6.623 (6.839) | −47.687 (3.313) | −39.937 (4.397) | 12.565 (6.040) | −35.592 (6.504) | −41.838 (3.490) |
Lp(a) | |||||||||
 Baseline (g/L) | 8.200 (3.550) | 9.859 (2.603) | 11.285 (2.671) | 2.776 (0.724) | 16.416 (6.548) | 13.424 (4.407) | 36.285 (16.171) | 16.013 (6.034) | 17.401 (4.244) |
 Percentage change from baseline to end of treatment (%) | −8.543 (4.712) | −34.074 (5.678) | −41.434 (7.972) | −15.471 (16.595) | −21.612 (9.532) | −47.521 (5.777) | −7.505 (7.441) | −34.300 (8.296) | −27.557 (6.045) |